The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2016Inhibition of Striatal-enriched Phosphate (STEP) to Improve Parkinson-related Cognitive Dysfunction
Promising Outcomes of Original Grant:
Our original funded project was designed to examine absorption and distribution of the STEP (Striatal-Enriched Phosphatase), a protein associated with several... -
Target Advancement Program, 2016Studying Monocyte Entry into the Brain in Alpha-synuclein-induced Parkinson's Disease
Study Rationale:
Alpha-synuclein is a sticky protein that clumps in the brains of people with Parkinson's disease (PD). In pre-clinical models, alpha-synuclein clumps attract scores of CCR2-positive... -
Research Grant, 2016Patient-Carer-Provider Communication about the Impact of Motor and Non-motor Fluctuations
Study Rationale:
Temporary periods of poor mobility and other symptoms (OFF periods) are common in Parkinson’s disease and are associated with poorer quality of life. OFF symptoms are complex, with... -
Therapeutic Pipeline Program, 2015Pharmacokinetics and CNS Distribution of IgG Antibodies: Quantitative Comparison of Blood-brain, Blood-CSF and CSF-brain Relationships After Intranasal and Intravascular Dosing
Study Rationale:
Immunotherapy using antibodies (large proteins) directed against alpha-synuclein is a promising, potentially disease-modifying treatment approach for... -
Research Grant, 2015Phase IB Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A in Those Who Participated in the AFF008 Program
Promising Outcomes of Original Grant:
Accumulation and/or aggregation of alpha-synuclein is central to the pathogenesis of Parkinson’s disease (PD), and its reduction is expected to positively modify... -
Therapeutic Pipeline Program, 2015The Tolerability of Buspirone for the Treatment of Anxiety in Parkinson’s Disease
Study Rationale:
Anxiety is a common non-motor symptom among individuals with Parkinson’s disease (PD) and is associated with a reduced quality of life. Despite this...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.